Plus Therapeutics announced on March 10, 2025, that it received confirmation from Nasdaq on March 7, 2025, regarding its compliance with Nasdaq’s minimum stockholders’ equity requirement. This ensures the company's continued listing on The Nasdaq Capital Market.
The company's common stock will continue to be listed and traded on The Nasdaq Capital Market. Maintaining this listing is crucial for liquidity and access to capital markets.
This compliance addresses a previous deficiency and is a positive development for the company's corporate governance and investor confidence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.